Drug Information Update- Anti-Infective Drugs Advisory Committee meeting on 10/27/09

Drug Information Update- Anti-Infective Drugs Advisory Committee meeting on 10/27/09

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
On October 27, 2009, Anti-Infective Drugs Advisory Committee will discuss Biologic License Application (BLA) 125349, for raxibacumab injection, manufactured by Human Genome Sciences, Inc., proposed for the treatment of inhalational anthrax disease.
For more information, please visit: Raxibacumab

abrir aquí:
http://edocket.access.gpo.gov/2009/pdf/E9-23143.pdf